Table 1 Comparison of baseline characteristics between both treatment arms
Vancomycin (n = 7) | Daptomycin (n = 7) | All (n = 14) | |
|---|---|---|---|
Age in years (median, IQR) | 70 (64, 71) | 65 (50, 71) | 67.5 (54.5, 71) |
Age > 65 years | 4 | 3 | 7 |
Gender | |||
Male | 5 | 5 | 10 |
Female | 2 | 2 | 4 |
Ethnicity | |||
Chinese | 4 | 6 | 10 |
Malay | 1 | 0 | 1 |
Indian | 1 | 1 | 2 |
Others | 1 | 0 | 1 |
Charlson comorbidity score (median, IQR) | 5 (4, 7) | 5 (4, 8) | 5 (4, 7) |
Diabetes mellitus prior to screening | 0 | 2 | 2 |
CKD prior to screening | 3 | 2 | 5 |
Diabetes mellitus and CKD prior to screening | 3 | 2 | 5 |
On vancomycin prior to study enrolment | 5 | 7 | 12 |
Duration of vancomycin treatment prior to enrolment, days (median, IQR) | 3 (3, 5) | 4 (3, 5) | 3.5 (3, 5) |
On daptomycin prior to study enrolment | 0 | 0 | 0 |
Diagnosis at enrolment | |||
Uncomplicated bacteremia | 7 | 5 | 12 |
Complicated bacteremia without endocarditis | 0 | 2 | 2 |
Endocarditis | 0 | 0 | 0 |
Vancomycin MIC (median, IQR) | 1.5 (1.5, 1.5) | 1.5 (1.5, 1.5) | 1.5 (1.5, 1.5) |